Rho-Associated Kinase Inhibitors: Evolving Strategies in Glaucoma Treatment
- 216 Downloads
Glaucoma, a group of progressive optic neuropathies with similar patterns of tissue loss, is primarily treated with medical therapy, followed by laser therapy and, later, incisional surgery. Aside from the introduction of prostaglandin analogs, topical carbonic anhydrase inhibitors, and topical alpha-agonists in the 1990s, no new pharmaceutical agents to lower intraocular pressure (IOP) have been introduced for approximately 20 years. The Rho kinase inhibitors represent a new class of glaucoma medications that inhibit the downstream pathway of the Rho family of small G-proteins to increase outflow from the conventional (trabecular) outflow pathway in the eye. Several of these Rho kinase inhibitors, ripasudil and netarsudil, have recently reached the market and are used in clinical practice in several countries. A fixed-dose combination of latanoprost and netarsudil was also very recently approved (2019) by the US FDA. Several other novel agents are undergoing clinical trials. These drugs are poised to act as adjuncts to already established medical therapy for further lowering of IOP in the treatment of glaucoma.
Compliance with Ethical Standards
Conflict of interest
Dr. Alan Robin serves as Executive Vice President of the American Glaucoma Society. Dr. Emily Schehlein has no conflicts of interest that are directly relevant to the content of this article.
No sources of funding were used to conduct this study or prepare this manuscript.
- 4.Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group (2002) Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (Chicago, Ill 1960) 120:1268–79.Google Scholar
- 7.Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO (2002) The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (Chicago, Ill 1960) 120:701–730.CrossRefGoogle Scholar
- 12.Abu-Hassan DW, Acott TS, Kelley MJ. The trabecular meshwork: a basic review of form and function. J Ocul Biol. 2014;2(1).Google Scholar
- 23.Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, Araie M. Additive intraocular pressure-lowering effects of the rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: a report of 2 randomized clinical trials. JAMA Ophthalmol. 2015;133:755–61.CrossRefGoogle Scholar
- 30.Sturdivant JM, Royalty SM, Lin C-W, Moore LA, Yingling JD, Laethem CL, Sherman B, Heintzelman GR, Kopczynski CC, deLong MA (2016) Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma. Bioorg Med Chem Lett. https://doi.org/10.1016/j.bmcl.2016.03.104.CrossRefGoogle Scholar
- 33.Serle JB, Katz LJ, McLaurin E, Heah T, Ramirez-Davis N, Usner DW, Novack GD, Kopczynski CC. Two Phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018;186:116–27.CrossRefGoogle Scholar
- 35.Aerie Pharmaceuticals Inc (2017) Aerie pharmaceuticals reports positive RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 topline efficacy results. https://www.businesswire.com/news/home/20170524006043/en/Aerie-Pharmaceuticals-Reports-Positive-RoclatanTM-netarsudillatanoprost-ophthalmic.
- 36.Bacharach, J., Khouri, A.S., Heah, T., Kopczynski C, Lewis R (2017) A double-masked, randomized, multi-center, active-controlled, parallel group, 6-month study assessing the ocular hypotensive efficacy and safety of netarsudil ophthalmic solution, 0.02% QD compared to timolol maleate ophthalmic solution, 0.5% BID in patie. Am Acad Optom Abst E351:(Oct 11–14, Chicago).Google Scholar
- 37.Lewis R a, Levy B, Ramirez N, C Kopczynski C, Usner DW, Novack GD (2015) Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol Bjophthalmol 2015:306778.Google Scholar
- 38.Aerie Pharmaceuticals Inc (2016) RoclatanTM mercury 2 phase 3 topline results. http://investors.aeriepharma.com/static-files/fb9a0c3f-7255-4b50-97b2-450a2ba5d139.